Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1529502 | 0.83 | DAO (0.63) | DAOGSK3BGPR35MEN1KMT2A | |
| SCHEMBL9777845 | 0.79 | DAO (0.42) | DAOGSK3BGPR35CES2CES1 | |
| SCHEMBL7040416 | 0.79 | DAO (0.69) | DAOGSK3BGPR35MEN1KMT2A | |
| SCHEMBL7043189 | 0.79 | GSK3B (0.57) | DAOGSK3BCES2CES1MEN1 | |
| SCHEMBL20486947 | 0.78 | DAO (0.42) | DAOGSK3BUSP2 | |
| SCHEMBL7043473 | 0.76 | DAO (0.44) | DAOGSK3BGPR35CES2CES1 | |
| SCHEMBL4382710 | 0.74 | GSK3B (0.70) | DAOGSK3BSTING1 | |
| SCHEMBL3900686 | 0.74 | GSK3B (0.67) | DAOGSK3BUSP2MEN1KMT2A | |
| SCHEMBL1529851 | 0.73 | DAO (0.43) | DAOGSK3BMEN1KMT2A | |
| SCHEMBL1177426 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613786-B2 | Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | HEWAWASAM PIYASENA (US) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | PDE3A, ADRB2, ADRB3 | DAO 3738/4885GSK3B 3398/4885GPR35 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.